Back to Search
RICHARD AMADO, PHD
PHD
Psychologist
NPI: 1619147576Individual
Specialties, Licenses & Credentials
PsychologistPrimary
Psychologist
Code: 103T00000X
LP0257(MN)
Research & Publications (20)
Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model.
PMID 18482274·Liver Int·2009
4-observational
Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy.
PMID 19189371·Cancer·2009
3-trial
An open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumors.
PMID 19203894·Clin Colorectal Cancer·2009
3-trial
A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.
PMID 19114685·J Clin Oncol·2009
3-trial
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
PMID 18316791·J Clin Oncol·2008
3-trial
An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy.
PMID 17785764·Ann Oncol·2008
3-trial
Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone.
PMID 18621636·Clin Colorectal Cancer·2008
8-other
Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies.
PMID 18223225·Clin Cancer Res·2008
3-trial
Physiological and metabolic properties of a digestion-resistant maltodextrin, classified as type 3 retrograded resistant starch.
PMID 17253707·J Agric Food Chem·2007
8-other
Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab.
PMID 18040272·Br J Cancer·2007
3-trial
From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice.
PMID 17921999·Nat Biotechnol·2007
7-preclinical
Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer.
PMID 17671985·Cancer·2007
3-trial
Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer.
PMID 17531105·Clin Colorectal Cancer·2007
3-trial
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.
PMID 17470858·J Clin Oncol·2007
3-trial
Influence of thermal processing conditions on acrylamide generation and browning in a potato model system.
PMID 16881694·J Agric Food Chem·2006
8-other
Investigations on the promoting effect of ammonium hydrogencarbonate on the formation of acrylamide in model systems.
PMID 17177568·J Agric Food Chem·2006
8-other
Authentication of the botanical and geographical origin of honey by mid-infrared spectroscopy.
PMID 16939352·J Agric Food Chem·2006
8-other
Authentication of the botanical origin of honey by near-infrared spectroscopy.
PMID 16939351·J Agric Food Chem·2006
8-other
Authentication of the botanical and geographical origin of honey by front-face fluorescence spectroscopy.
PMID 16939350·J Agric Food Chem·2006
7-preclinical
Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia.
PMID 16478746·J Natl Cancer Inst·2006
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 415 BLAKE RD N, STE 240
HOPKINS, MN 55343 - Phone
- (952) 814-0207
Quick Facts
- NPI
- 1619147576
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile